Clinical Trial Update: JY509 Universal NK Cell Injection for the Treatment of Relapsed/Refractory Pediatric B-ALL [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 clinical trial of JY509 universal NK cell injections for relapsed/refractory pediatric B-cell acute lymphoblastic leukemia (B-ALL) is not yet r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• JY509 Universal NK Cell Injection

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Relapsed/Refractory Pediatric B-ALL | EARLY_Phase 1 | Status: NOT_YET_RECRUITING